ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Medidata Wins Citeline Awards for myMedidata, the Most Comprehensive Patient Portal for Decentralized Clinical Trials, and its Holistic Digital Oversight Solution to Enable Clinical Monitoring Strategies

Medidata recognized for its exceptional innovations in life sciences, using technology to engage patients, optimize clinical trials, and accelerate the development of new therapeutics and vaccines

Medidata, a Dassault Systèmes company, is pleased to announce that it was recognized for its outstanding accomplishments in life sciences by the Citeline Awards:

  • Best Patient-Facing Technology Initiative for myMedidata, a single-destination web-based portal for patients to engage pre-trial, in-trial, and post-trial, built for patients, by patients.
  • Best Sponsor-Facing Technology Initiative for Medidata’s Digital Oversight Solution, which facilitates clinical trial data oversight and monitoring, improving timelines, cost, and quality in the execution of decentralized clinical trials (DCTs).

The Citeline Awards celebrate critical achievements across the spectrum of key R&D activities, from successes in early and late-stage research, to advances in technological tools, to innovations in trial design and execution. Medidata was presented with the awards in a ceremony held on April 7 in Boston.

myMedidata was recognized as a powerful, intuitive, patient-centric portal. The Citeline Best Patient-facing Technology Initiative recognizes the growing role of technology in facilitating participation in clinical trials and is awarded to the product which best advances patient data collection and improves overall patient experience. myMedidata enables patients to seamlessly connect with any online device to virtually learn about, enroll in and participate in clinical trial activities. It is the industry’s single most comprehensive, integrated tool set for all aspects of clinical research. It is built on Medidata’s industry leading Rave EDC (Electronic Data Capture) system, currently in use at more clinical research sites globally than any other system.

Medidata’s Digital Oversight Solution was commended for its transformative impact on all core activities of the trial process. Medidata’s Digital Oversight Solution has a unique position in the market, unifying risk management, centralized monitoring, and a robust clinical trial management system (CTMS) on one platform. This solution makes it possible for study teams to prepare for and analyze high volumes of data, at scale and in time to take action. The technology can move teams away from delayed, reactive methodologies to proactive and predictive strategies, as well as optimize physical and virtual interactions with clinical sites.

Sastry Chilukuri, co-CEO of Medidata, said, “The patient’s interest is at the core of what we do, which is why we have worked hard to pioneer products that make clinical trials more accessible and engaging. As the first company to leverage digital health technologies for DCTs, we are proud to have received the Citeline Awards for myMedidata and Medidata’s Digital Oversight Solution. We will continue to support the movement toward trial decentralization with ever-expanding offerings, which deliver high quality data and improve the patient experience.”

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,900+ customers and partners access the world's most trusted platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systèmes, a French “société européenne” (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  254.00
+9.78 (4.00%)
AAPL  269.05
-1.32 (-0.49%)
AMD  259.65
+3.53 (1.38%)
BAC  53.56
+0.11 (0.21%)
GOOG  284.12
+2.30 (0.82%)
META  637.71
-10.64 (-1.64%)
MSFT  517.03
-0.78 (-0.15%)
NVDA  206.88
+4.39 (2.17%)
ORCL  257.85
-4.76 (-1.81%)
TSLA  468.37
+11.81 (2.59%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.